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Abstract 
 
Recent studies highlighted the renoprotective effect of SIRT1, a deacetylase that contributes to cel-
lular regulation. However, its pathophysiological role in podocytes is unclear.  I thus investigated 
the function of SIRT1 in podocytes.  
  I made podocyte specific Sirt1 knockout (SIRT1
pod-/-
) mice by crossing Sirt1
flox/flox
 mice with po-
docin-Cre mice. Then, I induced glomerular damage by injection of sheep anti-glomerular basement 
membrane (GBM) antibody in SIRT1
pod-/-
 or wild-type mice. Seven days after the disease induction, 
both urinary albumin per creatinine ratio and BUN in SIRT1
pod-/- 
mice were significantly higher than 
those in wild-type mice and histological injury of glomeruli was also significantly increased in 
SIRT1
pod-/-
 mice. In western blot analysis of isolated glomeruli, podocyte specific molecules were 
significantly reduced in SIRT1
pod-/- 
mice, and these findings were confirmed by immunofluorescence 
study. By electron microscopy, I found that foot process effacement and actin cytoskeleton de-
rangement caused by glomerular disease induction were markedly exacerbated in SIRT1
pod-/-
 mice 
compared with wild-type mice. Similarly, in in vitro study, mild actin cytoskeleton derangement in 
H2O2-treated podocytes became prominent when the cells were pretreated with SIRT1 inhibitors, 
while an SIRT1 activator ameliorated the actin cytoskeleton derangement. Cellular motility was also 
reduced by pharmacological SIRT1 inhibition. Moreover, I assessed actin fiber-binding protein cor-
tactin, and found that SIRT1 deacetylated acetylated cortactin in nucleus and the deacetylated cortac-
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tin was transported to cytoplasm for maintenance of actin fiber. Taken together, SIRT1 maintains 
podocyte homeostasis and prevents glomerular injury by deacetylating cortactin and the subsequent 
maintenance of actin fiber integrity.  
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Introduction 
 
In kidney, a tubular structure called the nephron filters blood to form urine. A glomerulus is the be-
ginning of the nephron, which is a network of capillaries that performs the first step of filtering blood. 
The filtration barrier of the glomerulus consists of a fenestrated capillary epithelium, glomerular 
basement membrane (GBM) and the final barrier formed by podocyte. Podocytes, which are charac-
terized as visceral glomerular epithelial cells, are highly differentiated cells which play an essential 
role in maintenance of the glomerular tuft and filtration barrier. Foot processes (FPs) of adjacent po-
docytes regularly interdigitate to form narrow filtration slits that are bridged by the slit diaphragm 
(SD), a zipper-like structured modified adherens junction [1] (Figure 1S). Podocyte injury is a com-
mon feature in glomerular diseases [1-6]. Among several pathophysiological mechanisms of podo-
cyte injury, derangement of actin cytoskeleton is a critical pathological manifestation, because the 
actin cytoskeleton plays an essential role in maintaining the podocyte structure, including FPs. Actin 
fibers in podocytes function not only in the maintenance of cellular structure, but also in interactions 
with various molecules, including structural molecules in the SD [1], [7], [8] (Figure 2S). These 
findings strongly suggest that the maintenance of actin cytoskeleton is essential to glomerular func-
tion and podocyte homeostasis. 
 SIRT1 (Sirtuin1, silent mating type information regulation 2 [Sir2] homolog) is a 
NAD
+
-dependent deacetylase (Figure 3S) that regulates a variety of physiological phenomena such 
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as metabolism, stress response, DNA repair, inflammation, and longevity [9–15]. Most of the effects 
of SIRT1 depend on its deacetylation activity [9], [10] (Figure 4S). Recent studies have shown that 
SIRT1 is associated with a number of pathological conditions, including metabolic disorders, cardi-
ovascular diseases, neurodegenerative diseases and cancer in various organs [16–21] (Figure 5S). 
With regard to the kidney, SIRT1 is reported to have renoprotective functions [22], [23]. As exam-
ples, SIRT1 regulates glucose or lipid metabolism, blood pressure, and oxidative stress, which are all 
closely associated with kidney disease [24–28]. In addition, SIRT1 protects the proximal tubular 
[29–31], medullary [32], and mesangial cells [33], [34] (Figure 6S). However, the pathophysiological 
role of SIRT1 expressed in podocytes is unclear, and no report has described the establishment or use 
of podocyte-specific Sirt1 knockout mice. Although several studies have suggested the possibility of 
a protective effect of SIRT1 on podocytes [35], [36], the molecular mechanism of the function of 
SIRT1 expressed in podocytes remains unclear.  
 Here, I hypothesized that the protective effect of SIRT1 on podocytes results from its maintenance 
of actin cytoskeleton, which is a critical factor for podocyte homeostasis. To address this question, I 
established for the first time podocyte-specific Sirt1 knockout (SIRT1
pod-/-
) mice and investigated the 
effect of SIRT1 deletion in podocytes. 
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Materials and Methods 
 
Reagents and antibodies 
 
Three SIRT1 inhibitors were used: EX-527 (Tocris Bioscience, Bristol, UK), cambinol (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), and nicotinamide (Sigma-Aldrich, St. Louis, MO, USA). 
SIRT1 activator resveratrol was purchased from Tokyo Chemical Industry (Tokyo, Japan). Hydrogen 
peroxide (H2O2) was purchased from Wako Pure Chemical Industries (Tokyo, Japan) and used as a 
cellular damage inducer in vitro.  
Sheep anti-glomerular basement membrane (GBM) antibody was kindly provided by Dr. Reiko 
Inagi in my institute and the obtained antiserum was used as anti-GBM antibody. Polyclonal rabbit 
anti-SIRT1 (1:300; 07-131) antibody, monoclonal mouse anti-cortactin antibody (1:300; 05-180; 
clone 4F11), polyclonal rabbit anti-acetyl cortactin antibody (1:200; 09-881) and polyclonal rabbit 
anti-acetyl-histone H3 antibody (1:5000; 06-599) were purchased from Millipore (Billerica, MA, 
USA) and used for western blot analysis, immunoprecipitation or immunostaining. Polyclonal rabbit 
anti-WT-1 antibody (1:200; sc-192), polyclonal rabbit anti-synaptopodin antibody (1:200; sc-50459), 
polyclonal goat anti-nephrin antibody (1:100; sc-19000) and monoclonal mouse anti-histone H1 an-
tibody (1:100; sc-8030) were obtained from Santa Cruz Biotechnology and used for western blot 
analysis or immunofluorescence. Polyclonal rabbit anti-actin antibody (1:1000; A2066), polyclonal 
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rabbit anti-nitrotyrosine antibody (1:300; N0409), Texas Red-conjugated polyclonal rabbit anti-sheep 
antibody (1:20; SAB3700695), and monoclonal mouse anti-α-tubulin antibody (1:1000; T6199, 
clone DM1A) were purchased from Sigma-Aldrich. As secondary antibody for immunohistochemis-
try, biotinylated goat anti-rabbit IgG antibody (1:1000; BA-1000) was obtained from Vector Labora-
tories (Burlingame, CA, USA). Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:10000; 
170-6516; Bio-Rad Laboratories, Hercules, CA, USA), HRP-conjugated goat anti-rabbit IgG 
(1:10000; 170-6515; Bio-Rad Laboratories) or HRP-conjugated donkey anti-goat IgG (1:500; 
sc-2020; Santa Cruz Biotechnology) were used as secondary antibodies for western blot analysis. For 
immunofluorescence study, fluorescein isothiocyanate (FITC)-conjugated polyclonal swine an-
ti-rabbit immunoglobulin antibody (1:20; F0205; Dako, Carpinteria, CA, USA), Texas 
Red-conjugated goat anti-rabbit IgG (H+L) (1:20; T2767; Invitrogen, Eugene, OR, USA), Alexa 
Fluor 546-conjugated goat anti-mouse IgG (H+L) (1:200, A11003, Invitrogen) or FITC-conjugated 
goat anti-mouse IgG (1:200, 1070-02, Southern Biotechnology Associates, Birmingham, AL, USA) 
was used as secondary antibody. Alexa Fluor 488 phalloidin (1:40) was purchased from Invitrogen 
and used for detection of actin fiber in vitro. Hoechst 33258 (1:10000, Sigma-Aldrich) was used for 
the detection of nucleus. 
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Animal experiments 
 
Podocyte-specific Sirt1 knockout (SIRT1
pod-/-
) mice were established by crossing podocin-Cre mice 
[37] on C57BL/6J background with Sirt1
flox/flox
 mice on the same background, as described previ-
ously (kindly provided by Dr. Kazuyuki Tobe, University of Toyama). To evaluate the basal state of 
SIRT1
pod-/-
 mice, I measured body-weight, blood pressure, pulse rate, blood urea nitrogen (BUN) and 
urinary-albumin creatinine ratio (U-alb/cre) in male SIRT1
pod-/-
 mice and wild-type mice at 13-14 
weeks of age. For glomerular disease induction, male SIRT1
pod-/-
 and wild-type mice were adminis-
tered sheep anti-GBM antibody (0.7 ml/kg) at 13-14 weeks of age. Seven days after administration, 
serum and urine (24-h) were collected to measure BUN and U-alb/cre. The experimental mice were 
then sacrificed and the kidneys were removed for histological analysis or isolation of glomeruli.  
   
Isolation of glomeruli  
 
Glomeruli were isolated using a previously described method [38], with some modification. Briefly, I 
placed a catheter into the aorta of the mouse, and perfused magnetic Dynabeads (Invitrogen) through 
the catheter. After removal, kidneys were minced into small pieces, digested by collagenase and 
DNase, and filtered. After washing several times, the glomeruli were collected using a magnet. The 
purity of glomeruli was confirmed to be more than 95% in each sample by phase-contrast microsco-
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py.  
 
Histological analysis of glomeruli by PAS staining and immunohistochemistry 
 
Glomerular injury was evaluated by optical microscopy of formalin-fixed sections (3-μm thickness) 
stained with Periodic acid-Schiff (PAS) reagent. For quantitative comparison, 100 glomeruli were 
observed and the number of damaged glomeruli, such as those with crescent formation or tuft necro-
sis, was counted. The ratio of injured glomeruli to all glomeruli was calculated for every group of 
mice. 
In immunohistochemical analysis, kidneys were fixed in formalin solution or methyl Carnoy’s so-
lution and embedded in paraffin. Sections of 3-μm thickness were incubated with primary antibody 
for 12 h at 4 °C, then with biotinylated secondary antibodies for 1 h, and HRP-conjugated avidin D 
(1:2000; A-2004; Vector Laboratories) for 30 minutes. Color was developed by incubation with dia-
minobenzidine and hydrogen peroxide (Wako Pure Chemical Industries) at 37 °C.  
 
Immunofluorescence study 
 
Kidneys were removed from mice, embedded in O.C.T. compound (Sakura Finetek Japan, Tokyo, 
Japan), and frozen on dry ice. The frozen block was cut into 4-μm sections, which were then fixed in 
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methanol/acetone (1:1) and incubated with primary antibody for 12 h. They were subsequently incu-
bated with fluorescence-conjugated secondary antibody and/or fluorescence-conjugated probes for 1 
h in dark conditions.   
 
Electron microscopy 
 
For electron microscopic examination, kidney tissue was fixed in 2.5% glutaraldehyde solution in 
phosphate buffer (pH 7.4), then postfixed with 1% osmium tetroxide, dehydrated, and embedded in 
Epok 812. Ultrathin sections were stained with uranyl acetate and lead citrate, and then examined 
with an electron microscope (model H7100, Hitachi Corp., Tokyo, Japan). 
 
Cell culture 
 
Conditionally immortalized murine podocytes were generated and characterized as described previ-
ously [39]. The cells were grown in RPMI 1640 media (Nissui Pharmaceutical, Tokyo, Japan) con-
taining 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Waltham, MA, USA), penicillin 
(50 U/mL), streptomycin (50 μg/mL), sodium pyruvate (1 mmol/L) (Life Technologies, Carlsbad, 
CA, USA), HEPES buffer (10 mmol/L) (Sigma-Aldrich) and sodium bicarbonate (0.075%) (Nissui 
Pharmaceutical). To passage cells, podocytes were grown under permissive conditions (33 °C in the 
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presence of interferon-gamma (IFN-γ, 50 U/mL)). For podocytes to acquire differentiation and qui-
escence, resembling the in vivo phenotype, cells were grown under restrictive conditions at 37 °C in 
95% air/5% CO2 without IFN-γ for longer than 11 days. All experiments were performed utilizing 
podocytes under growth-restricted, differentiated conditions. 
 
Western blot analysis and immunoprecipitation 
 
For western blot analysis, cultured cells or isolated glomeruli were lysed by the addition of lysis 
buffer containing 50 mM Tris-buffer (pH8.0), 100 mM NaCl, 5 mM EDTA, 1% NP40, and 1% Tri-
ton X-100. Protein concentration was measured with a DC protein kit (Bio-Rad Laboratories). SDS 
sample buffer containing 0.35 M Tris-HCl (pH 6.8), 10% SDS, 36% glycerol, 5% β-mercaptoethanol, 
and 0.012% bromophenol blue was added to the lysate. Cytoplasmic or nuclear extract of the cells 
was obtained using an NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific, 
Waltham, MA, USA), and the SDS sample buffer was added to the extract solution. The proteins 
were separated by 8% or 12% SDS-polyacrylamide gels. After electrophoresis, the proteins were 
transferred onto a polyvinylidene difluoride (PVDF) transfer membrane (GE Healthcare, Bucking-
hamshire, England, UK) in a Tris-glycine transfer buffer (48 mM Tris-buffer, 39 mM glycine, 0.05% 
SDS, 10% methanol). Membranes were incubated in primary and secondary antibodies, and an ECL 
Plus Western blotting system (GE Healthcare, Buckinghamshire, England, UK) was used for detec-
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tion. Reproducibility was confirmed in at least three independent experiments, and representative 
data are presented in the figures. The intensity of bands was quantified using the NIH Image J soft-
ware (National Institutes of Health, Bethesda, MD, USA).  
For immunoprecipitation, the cells were lysed by Triton cell lysis buffer containing 1 M 
Tris-buffer (pH7.4), 100 mM NaCl, 5 mM EDTA, 10 mM sodium pyrophosphate (Sigma-Aldrich), 
200 μM, Na3VO4 (Wako Pure Chemical Industries), and 1% Triton X-100. A 1-ml cell extract con-
taining 300- 400 μg protein was incubated with 5-10 μg target antibody or control IgG overnight at 
4 °C, and subsequently incubated with 30 μg protein G sepharose (GE Healthcare) for 2 h at 4 °C. 
Proteins bound to the beads were eluted by boiling at 95 °C for 5 minutes, and the extract solution 
was used for Western blot analysis.   
 
Immunocytochemistry  
 
In experiments using SIRT1 inhibitors, podocytes were incubated in media with EX-527 (100 μM), 
cambinol (50 μM), nicotinamide (10 mM) or vehicle (ethanol) for 24 h. The media was then ex-
changed with media containing H2O2 (300 μM) or vehicle and incubation was continued for 24 h to 
expose cells to mild oxidative stress. In experiments using the SIRT1 activator resveratrol, podocytes 
were incubated in media with resveratrol (200 μM) for 3 h, then incubated in media with H2O2 (700 
μM) for 1 h to cause strong oxidative stress.   
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To assess actin fibers and cellular morphology, cells were fixed in 4% paraformaldehyde solution, 
permeabilized in 0.3% Triton X solution, and incubated with Alexa Fluor 488 phalloidin (1:40 dilu-
tion) in darkness. To detect other molecules, fixed and permeabilized cells were incubated with pri-
mary antibody for 12 h and subsequently incubated with fluorescence-conjugated secondary anti-
body for 1 h in darkness. A BZ-9000 fluorescence microscope (Keyence, Osaka, Japan) was used for 
observation. 
 
Scratch assay 
 
Podocytes were seeded and differentiated in six-well plates. Each well was scratched with a sterile 
200-μl pipette tip and incubated in medium with an SIRT1 inhibitor or vehicle (ethanol). After 3 days’ 
incubation, the migration of cells in each stimulation group was observed. Cells were photographed 
under phase-contrast microscopy on days 0 and 3 after scratching, and the number of cells migrated 
into the scratched area was counted. The results were confirmed by three independent experiments 
for each SIRT1 inhibitor.   
 
Statistical analysis 
 
All data are reported as means ± SE. Data for two groups were analyzed with Student’s t-test, and 
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those for more than two groups were compared by analysis of variance with Bonferroni’s post hoc 
test. Differences with a p value of <0.05 were considered significant. GraphPad Prism software ver-
sion 5.04 for Windows (GraphPad Software, San Diego, CA, USA) was used for data analysis.  
 
Study approval 
 
All animal procedures were conducted in accordance with the guidelines for the care and use of la-
boratory animals approved by the University of Tokyo School of Medicine (M-P12-66). 
16 
 
Results  
 
Glomerular injury induced by anti-GBM antibody is significantly exacerbated in podo-
cyte-specific SIRT1
pod-/-
 mice.   
 
In this study, I used podocyte-specific Sirt1 knockout (SIRT1
pod-/-
) mice, established by crossing 
Sirt1
flox/flox
 mice with podocin-Cre mice, to investigate the function of SIRT1 in podocytes. SIRT1 
deletion in SIRT1
pod-/-
 mice was confirmed by western blot analysis utilizing isolated glomeruli from 
SIRT1
pod-/-
 and wild-type mice (Figure 1A). Data for blood urea nitrogen (BUN) (23.91±0.83 mg/dl 
in wild-type mice and 25.98±0.89 mg/dl in SIRT1
pod-/-
 mice), urinary albumin creatinine ratio 
(U-alb/cre, 0.43±0.06 in wild-type mice and 0.53±0.08 in SIRT1
pod-/-
 mice), and other physiological 
variables did not differ between SIRT1
pod-/-
 and wild-type mice (Figure 1B, 1C, Table 1). Further, I 
observed no histological changes in the kidney of SIRT1
pod-/-
 mice on Periodic acid-Schiff (PAS) 
staining (Figure 1D, 1E).  
 I then induced glomerular damage by injection of sheep anti-GBM antibody (anti-GBM glomeru-
lonephritis) in SIRT1
pod-/-
 and wild-type mice. Seven days after disease induction, the ratio of dam-
aged glomeruli was significantly higher in SIRT1
pod-/-
 mice (Figure 1D, 1E). Both U-alb/cre 
(35.76±4.87 in wild-type mice vs. 86.85±18.44 in SIRT1
pod-/-
 mice) and BUN (22.10±0.97 mg/dl in 
wild-type mice vs. 25.88±1.05 mg/dl in SIRT1
pod-/-
 mice) were also significantly exacerbated in 
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SIRT1
pod-/-
 mice compared with wild-type mice (Figure 1F, 1G). I confirmed that the level of binding 
of anti-GBM antibodies to glomeruli in the two groups was similar (Figure 1H). Because the podo-
cyte-specific deletion of SIRT1 induced glomerular vulnerability, I then focused on the critical func-
tion of SIRT1 in the maintenance of podocyte homeostasis and subsequent glomerular function and 
structure.  
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Figure 1. Glomerular injury and renal dysfunction were exacerbated in podocyte-specific Sirt1 
knockout (SIRT1
pod-/-
) mice with glomerular disease.  
(A) Western blot analysis using isolated glomeruli from wild-type or SIRT1
pod-/-
 mice. A reduction in 
SIRT1 expression in SIRT1
pod-/-
 mice was confirmed. (B) Blood urea nitrogen (BUN) level of 
wild-type (n=18) and SIRT1
pod-/-
 mice (n=21). (C) Urinary albumin per creatinine ratio of wild-type 
(n=18) and SIRT1
pod-/-
 mice (n=21). n.s., not significant. 
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Figure 1 (cont.). 
(D) Histological analysis by PAS staining. At 7 days after glomerular disease induction with an-
ti-GBM antibody injection, glomerular damage was more severe in SIRT1
pod-/-
 mice than in 
wild-type mice. Scale bars, 100 μm. (E) Ratio of injured glomeruli in PBS-injected wild-type (n=6) 
or SIRT1
pod-/- 
mice (n=7) and wild-type (n=9) or SIRT1
pod-/-
 mice (n=9) with anti-GBM glomerulo-
nephritis (*** p<0.001). Glomerular damage in SIRT1
pod-/- 
mice with anti-GBM glomerulonephritis 
was significantly worse than that in wild-type mice.  
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Figure 1 (cont.). 
(F, G) BUN (F) or urinary albumin levels (G) in experimental mice. Seven days after anti-GBM 
glomerulonephritis induction, blood and urine were collected from PBS-injected wild-type (n=6) and 
SIRT1
pod-/-
 (n=8) mice and anti-GBM glomerulonephritis-induced wild-type (n=11) and SIRT1
pod-/-
 
(n=15) mice. Both BUN and urinary albumin levels were significantly higher in SIRT1
pod-/-
 mice than 
in wild-type mice under disease conditions (* p<0.05, *** p<0.001). (H) Detection of anti-GBM an-
tibody in the glomeruli of experimental mice. Immunofluorescence analysis showed a similar level 
of anti-GBM antibody binding to GBM in wild-type and SIRT1
pod-/-
 mice, indicating disease induc-
tion in both groups was identical. Scale bars, 100 μm. 
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Podocyte injury is exacerbated by deficiency of podocyte SIRT1
 
expression in anti-GBM glo-
merulonephritis. 
 
I next determined the effect of SIRT1 on podocyte homeostasis by assessing the change in the ex-
pression of podocyte-specific molecules. On western blot analysis using the lysate of isolated glo-
meruli of the mice, the expression of nephrin, synaptopodin, and Wilms tumor 1 protein (WT-1) after 
the induction of anti-GBM glomerulonephritis was significantly decreased in SIRT1
pod-/-
 mice com-
pared with wild-type mice (Figure 2A). I confirmed that the expression of actin was not changed and 
that this variable could therefore be used as an internal control by comparison with the expression of 
α-tubulin (Figure 2A). Immunofluorescent studies showed that SIRT1pod-/- and wild-type mice had 
similar synaptopodin and WT-1 expression before disease induction and decreased expression after 
induction, but that this decrease was greater in SIRT1
pod-/-
 mice (Figure 2B, 2C). These results are 
compatible with the exacerbation of histological and biochemical data in anti-GBM anti-
body-injected SIRT1
pod-/-
 mice shown in Figure 1. 
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Figure 2. Podocyte slit diaphragm (SD) damage was exacerbated by SIRT1 deficiency in vivo. 
(A) Podocyte injury level in isolated glomeruli of wild-type or podocyte-specific Sirt1 knockout 
(SIRT1
pod-/-
) mice at 7 days after anti-GBM glomerulonephritis induction. Western blot analysis 
followed by densitometry was performed to assess podocyte injury level, as estimated by the 
expression of SD-related proteins such as nephrin, synaptopodin (Synpo), and WT-1. For densi-
tometry, actin was used as an internal control. α-Tubulin expression was also assessed to con-
firm that the expression of actin was not changed in SIRT1-deficient podocytes. Expression of 
these SD-related proteins was significantly reduced in SIRT1
pod-/-
 mice compared with wild-type 
mice (* p<0.05).  (B, C) Representative immunohistochemical pictures of synaptopodin (B) or 
WT-1(C) in experimental mice. Decreased SD-related protein expression was severe in an-
ti-GBM glomerulonephritis-induced SIRT1
pod-/-
 mice compared with wild-type mice. Scale bars, 
20 μm.   
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Foot process effacement and actin fiber derangement are exacerbated by podocyte-specific 
Sirt1 knockout.    
 
To elucidate the mechanism by which SIRT1 deficiency deranges podocyte homeostasis in podocytes, 
I evaluated structural alterations in podocytes in SIRT1
pod-/-
 mice by electron microscopy. Following 
anti-GBM antibody injection, foot process effacement was more widespread and more severe in 
SIRT1
pod-/-
 than in wild-type mice, and the accumulation of actin fibers, which indicates actin cyto-
skeleton derangement, was higher (Figure 3). These findings are consistent with the marked increase 
in albuminuria in SIRT1
pod-/-
 mice with anti-GBM glomerulonephritis (Figure 1G). These results 
suggest that the major features of podocyte vulnerability following Sirt1 knockout were disruption of 
the actin cytoskeleton and slit diaphragm, and that these lead to the exacerbation of glomerular inju-
ry.  
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Figure 3. Foot process effacement and disruption of actin cytoskeleton were exacerbated in 
podocyte-specific Sirt1 knockout (SIRT1
pod-/-
) mice.  
Electron microscopic images of glomeruli of anti-GBM glomerulonephritis-induced wild-type (a, c, 
e) and SIRT1
pod-/-
 (b, d, f) mice. In SIRT1
pod-/-
 mice, foot process effacement was severe (b) com-
pared with that in wild-type mice (a). The lower panels (e and f) are enlargements of the parts indi-
cated by arrows in the middle panels (c and d). Actin fiber accumulation (arrow heads) was also in-
creased by SIRT1 deficiency in podocytes. Scale bars, 2 μm.  
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SIRT1 activity is necessary for maintenance of actin cytoskeleton in cultured podocytes 
 
To assess the effect of SIRT1 on actin fiber dynamics, I investigated structural changes in cultured 
murine podocytes treated with or without SIRT1 inhibitors. I used hydrogen peroxide (H2O2) to in-
duce cellular damage in in vitro experiments on the basis that oxidative stress, estimated by nitro-
tyrosine staining, was significantly induced in glomerular cells, including podocytes, of anti-GBM 
glomerulonephritis mice (Figure 4A). The cultured podocytes were pretreated with the SIRT1 inhib-
itor EX-527 (100 μM) or vehicle (ethanol) for 24 h, incubated with or without H2O2 (300 μM) for 24 
h, then stained for actin fiber using Alexa Fluor 488 phalloidin. The SIRT1 inhibitory effect of 
EX-527 was confirmed by western blot analysis for acetyl-histone H3 (Figure 4B). While mild de-
rangement of actin cytoskeleton was seen in the podocytes treated with either H2O2 or EX527, severe 
derangement was seen in SIRT1-inactived podocytes treated with H2O2 (Figure 4C). Similar results 
were observed in experiments using other SIRT1 inhibitors such as cambinol or nicotinamide (NAM) 
instead of EX-527 (Figure 4C). These results suggest that SIRT1 activity is necessary for the 
maintenance of actin fiber. 
I next confirmed the effect of SIRT1 on maintenance of actin cytoskeleton using resveratrol, a SIRT1 
activator. Pretreatment with resveratrol (200 μM) prevented the derangement induced in cultured 
podocytes by a high concentration of H2O2 (700 μM) (Figure 4D). I confirmed that a change in 
SIRT1 activity did not influence the expression of actin by western blot analysis in comparison with 
α-tubulin (Figure 4A). These loss-of- and gain-of-function analyses revealed that SIRT1 function is 
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associated with maintenance of the actin cytoskeleton.  
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Figure 4. SIRT1 activity was necessary for actin cytoskeleton maintenance in podocytes.  
(A) Oxidative stress detection by immunohistochemistry for nitrotyrosine in glomeruli of control or 
anti-GBM glomerulonephritis-induced mice. In anti-GBM antibody-injected mice, podocytes were 
positive for nitrotyrosine, indicating that oxidative stress was induced by anti-GBM glomerulone-
phritis. Scale bar, 50 μm. (B) Western blot analysis and densitometry for acetyl-histone H3 
(Ac-HisH3) in cultured podocytes (* p<0.05, ** p<0.01). EX527, a SIRT1 inhibitor, significantly 
increased acetylation level of histone H3 in a dose-dependent manner in podocytes.  
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Figure 4 (cont.). 
(C) Detection of actin fiber by fluorescein-phalloidin staining in cultured podocytes. Lower panels 
are enlargements. Cultured podocytes were treated with SIRT1 inhibitors (EX527, 100 μM; cambinol, 
50 μM; or nicotinamide (NAM), 10 mM) or vehicle (Vehi, ethanol) for 24 h and then treated with or 
without H2O2 (300 μM) for 24 h. H2O2 was used to induce podocyte injury to mimic that in an-
ti-GBM glomerulonephritis. Actin cytoskeleton derangement was markedly deteriorated in podocytes 
treated with both EX527 and H2O2 compared with the cells treated with either EX527 or H2O2. Sim-
ilar results were confirmed using the other SIRT1 inhibitors cambinol or NAM. Scale bars, 50 μm.  
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Figure 4 (cont.). 
(D) Fluorescein-phalloidin staining of cultured podocytes treated with SIRT1 activator under oxida-
tive stress conditions. Lower pictures are enlargements. Cultured podocytes were pretreated with 
SIRT1 activator resveratrol (RSV, 200 mM) or vehicle (Vehi, ethanol) for 3 h, then cultured with 
high dose H2O2 (High H2O2, 700 μM) for 1 h. RSV prevented actin cytoskeleton derangement in-
duced by oxidative stress. Scale bars, 50 μm.  
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Podocyte motility is reduced by SIRT1 inhibition.  
 
Because the cellular motility of podocytes is dependent on their dynamic assembly of actin [40–43], 
I hypothesized that podocyte migration ability is attenuated when the actin fibers are disrupted by 
SIRT1 inhibition. To address this, I examined the change in cellular motility by scratch assay utiliz-
ing cultured podocytes. Motility was markedly reduced by EX-527 treatment compared with vehicle 
(Figure 5A). Similar results were observed using other SIRT1 inhibitors (Figure 5B, 5C). These 
findings suggest that SIRT1 activity plays an essential role in actin fiber dynamics. 
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Figure 5. SIRT1 activity contributed to podocyte motility.  
SIRT1 activity contributed to podocyte motility. Scratch assay followed by counting of migrated po-
docytes treated with the SIRT1 inhibitions EX527 (A), cambinol (B), or nicotinamide (C). The cells 
were cultured with 100 μM EX527, 50 μM cambinol, or 5 mM nicotinamide (NAM) for 3 days after 
scratch, and then the number of migrated cells was counted. Inhibition of SIRT1 activity significantly 
retarded podocyte migration (* p<0.05, ** p<0.01, *** p<0.001). Results were confirmed by three 
independent experiments. Scale bars, 200 μm. 
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 SIRT1 deacetylates cortactin in nuclei of podocytes 
 
Cortactin, an actin-associated protein, interacts with actin fibers, and polymerizes and stabilizes them 
[40], [44] (Figure 7S). Some reports demonstrated that the acetylation state of cortactin contributes to 
the cell motility and mobility of cancer cells [44–46]. I therefore investigated the effect of SIRT1 on 
the acetylation state of cortactin and subsequent actin cytoskeleton maintenance and dynamics in 
podocytes. On western blot analysis, the ratio of acetylated cortactin to total cortactin was increased 
in cultured podocytes treated with SIRT1 inhibitors in a dose-dependent manner (Figure 6A, 6B). 
Conversely, this ratio was reduced in resveratrol-treated podocytes (Figure 6C). Moreover, these in 
vitro data were consistent with an in vivo study demonstrating that the level of acetylated cortactin in 
isolated glomeruli from SIRT1
pod-/-
 mice was significantly high compared to that in wild-type mice 
(Figure 6D). This interaction between SIRT1 and cortactin was confirmed in immunoprecipitation 
analysis in cultured podocytes (Figure 6E) and in immunofluorescence analysis, which showed that 
SIRT1 was colocalized with cortactin in nuclei (Figure 6F). These data suggest that SIRT1 deacety-
lates cortactin in the nuclei of podocytes and maintains of actin cytoskeleton, resulting in podocyte 
homeostasis.    
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Figure 6. SIRT1 regulated cortactin acetylation in vitro and in vivo.  
(A, B, C) Western blot analysis of acetylated cortactin (Ac-cort) and total cortactin in the whole cell 
extract of cultured podocytes treated with the SIRT1 inhibitors EX527 (A) or cambinol (B), or the 
SIRT1 activator resveratrol (RSV, C). Right panels show quantitative analyses of the ratio of Ac-cort 
to cortactin (* p<0.05, ** p<0.01). The ratio of Ac-cort was significantly increased by EX527 or 
cambinol in a dose-dependent manner, whereas it was decreased by RSV. (D) Western blot analysis 
of Ac-cort and total cortactin in the isolated glomeruli of wild-type or SIRT1
pod-/-
 mice. Quantitative 
analysis of the ratio of Ac-cort to cortactin is shown in the right panel (** p<0.01). The ratio of 
Ac-cort was significantly increased in SIRT1
pod-/-
 mice compared with wild-type mice. 
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Figure 6 (cont.). 
(E) Immunoprecipitation analysis for the detection of SIRT1 binding with cortactin. Whole-cell ex-
tract of cultured podocytes without stimulation was immunoprecipitated with anti-cortactin antibody 
or normal anti-rabbit IgG, and the precipitate was analyzed by western blot analysis using an-
ti-SIRT1 or anti-cortactin antibodies. A protein sample without immunoprecipitation was also ana-
lyzed (input) as a control. The results showed that SIRT1 interacts with cortactin. (F) Immunofluo-
rescence analysis for detection of SIRT1 and cortactin in cultured podocytes. Staining of SIRT1, 
cortactin, nuclei (Hoechst33258) and a merged image are shown. The merged figure shows that 
SIRT1 was colocalized with cortactin in the nuclei, suggesting that SIRT1 colocalizes with cortactin 
in the nuclei. Scale bar, 100 μm.  
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SIRT1 regulates actin cytoskeleton dynamics via acetylation of cortactin in podocytes.  
 
Finally, I investigated the change in cortactin localization by acetylation and its contribution to actin 
cytoskeleton maintenance and dynamics. Immunocytochemistry demonstrated that total (acetylated 
and deacetylated) cortactin was localized both in the cytoplasm and nucleus, and that the cytoplasmic 
cortactin was partly colocalized with actin fibers. When actin cytoskeleton derangement was induced 
by H2O2 in cells treated with EX527, the fiber-like distribution of cytoplasmic cortactin was simul-
taneously disrupted, and cortactin was dissociated from actin fiber (Figure 7A, 7B). In contrast to 
total cortactin, acetylated cortactin was localized only in the nucleus, and remained colocalized with 
SIRT1 regardless of the state of actin cytoskeleton (Figure 8A, 8B). I confirmed the localization of 
acetylated cortactin in podocytes in vivo (Figure 8C). Taking these findings together, I speculated 
that the deacetylation of cortactin by SIRT1 regulates the interaction with actin fibers.    
I then assessed the effect of SIRT1 on the acetylation level of cortactin in the cytoplasm and nu-
cleus of cultured podocytes. In nuclear extract, acetylated cortactin was increased by SIRT1 inhibi-
tion, as observed in the experiments using whole cell lysate, whereas acetylated cortactin was not 
detected in cytoplasmic extract (Figure 8D, 8E). Furthermore, the nuclear cortactin level was in-
creased, while that of cytoplasmic cortactin was conversely decreased (Figure 8D, 8E). These results 
suggest that cortactin is predominantly deacetylated by SIRT1 in the nucleus, and that deacetylated 
cortactin is transported from the nucleus to the cytoplasm, where it maintains actin cytoskeleton. The 
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deacetylation activity of SIRT1 is thus necessary for cortactin function and its transport from the nu-
cleus to cytoplasm.  
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Figure 7. SIRT1 maintained actin cytoskeleton by regulation of cortactin deacetylation.  
(A) Detection of cortactin by immunofluorescence in cultured podocytes treated with SIRT1 inhibi-
tor under oxidative stress. Staining of cortactin, actin fibers (phalloidin), nuclei (Hoechst33258), and 
their merged image are shown. Cultured podocytes were treated with vehicle (Vehi, ethanol) or 
EX527 (SIRT1 inhibitor, 100 μM) for 24 h, and subsequently incubated for 24 h with or without 
H2O2 (300 μM). In vehicle treated-cells cortactin was observed in both cytoplasm and nucleus, and 
cytoplasmic cortactin was partly colocalized with actin fibers. Cells treated with either H2O2 or 
EX527 showed moderate actin cytoskeleton derangement and partial disruption of the fiber-like dis-
tribution of cortactin. Treatment with both EX527 and H2O2, namely inhibition of SIRT1 activity 
under oxidative stress conditions, produced severe derangement of actin cytoskeleton and the appar-
ent absence of fiber-like distribution of cytoplasmic cortactin; in contrast, no changes in nuclear cor-
tactin were observed. Scale bar, 100 μm.  
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Figure7 (cont.).  
(B) Enlargements of the merged images shown in (A). Actin cytoskeleton derangement associated 
with the disruption of fiber-like distribution of cytoplasmic cortactin is clearly observed in 
SIRT1-inhibited podocytes under oxidative stress conditions. Scale bar, 50 μm.  
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Figure 8. SIRT1 deacetylated cortactin in the nuclei of podocytes. 
(A, B) Detection of acetyl-cortactin (A) and SIRT1 (B) by immunofluorescence in cultured podo-
cytes treated with SIRT1 inhibitor under oxidative stress. Cultured podocytes were analyzed for 
staining of acetyl-cortactin (Ac-cort) (A) or SIRT1 (B), with actin fiber (phalloidin) and nuclei 
(Hoechst 33258). Acetylated cortactin was observed only in nuclei regardless of the state of actin 
cytoskeleton in association with colocalization of SIRT1. Scale bar, 100 μm. (C) Immunostaining of 
acetyl-cortactin in the kidney of PBS-injected wild-type and anti-GBM glomerulonephritis-induced 
SIRT1
pod-/-
 mice. Lower images are enlargements focusing on podocytes (arrow heads). In the podo-
cytes, acetyl-cortactin was detected only in nuclei in both mice, which was compatible with the re-
sults in vitro shown in (A). Scale bars, 20 μm.  
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Figure8 (cont.).  
(D, E) Detection of cortactin by western blot analysis using the cytoplasmic (D) or nuclear extract 
(E) of cultured podocytes. Cells treated with EX527 (SIRT1 inhibitor, 100 μM) were analyzed for 
acetylated or total cortactin and their expression levels were quantitatively analyzed. (* p<0.05, ** 
p<0.01). Actin and histone H1 were used as internal controls of cytoplasmic and nuclear extracts, 
respectively. Total cortactin level in cytoplasm was reduced by SIRT1 inhibition, whereas nuclear 
cortactin level was conversely increased in association with nuclear accumulation of acetyl-cortactin. 
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Figure 9. SIRT1 maintains podocyte homeostasis by deacetylation of cortactin.  
In the normal state, SIRT1 deacetylates and activates cortactin, and the deacetylated cortactin func-
tions for the maintenance of actin cytoskeleton in the cytoplasm, leading in turn to the maintenance 
of podocyte homeostasis. As a result, the glomerulus, including the slit diaphragm, is maintained. 
Conversely, suppression of SIRT1 induces an increase in acetylated cortactin in the nucleus and de-
crease in active cortactin in the cytoplasm, which leads to the derangement of actin cytoskeleton, 
with consequent podocyte dysfunction or podocyte vulnerability leading to slit diaphragm injury, 
followed by glomerular injury. 
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Discussion 
 
In this study, I established SIRT1
pod-/-
 mice. Podocyte-specific Sirt1 knockout mice showed no bio-
chemical or histological abnormalities in the kidney. However, pathological alterations, such as FP 
effacement and actin fiber derangement, were significantly exacerbated in the podocytes of 
SIRT1
pod-/-
 mice after glomerular disease induction (anti-GBM glomerulonephritis), and in cultured 
podocytes with modulated SIRT1 activity under oxidative stress conditions as a mimic of anti-GBM 
glomerulonephritis. Importantly, I also found that SIRT1 deacetylated cortactin, an actin fi-
ber-associated molecule, and thereby enhanced cortactin activity, with subsequent polymerization 
and stabilization of actin fibers. My study reveals that SIRT1 has the novel function in podocytes of 
maintaining actin cytoskeleton and subsequently the structure of SD via the deacetylation of cortac-
tin. Further, it indicates the possibility that SIRT1 is essential to the protection of podocyte function 
as well as structure against pathogenic microenvironments, such as oxidative stress. My results 
therefore clarify the novel beneficial effect of SIRT1 on podocyte homeostasis.  
The cytoskeletal element of FP is composed of actin fibers only, indicating that actin fibers are es-
sential to maintenance of the structure and function of SD [47]. Mutations of actin fiber binding pro-
teins, such as α-actinin-4 or CD2AP, lead to podocyte injury owing to disorganization of the actin 
cytoskeleton and disruption of its filtration barrier [43], [48], [49]. I performed a scratch assay and 
showed that SIRT1 was necessary for podocyte motility. Although the question of whether motile 
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podocytes induce proteinuria and renal damage is still controversial [8], [43], it is widely accepted 
that the reorganization of actin cytoskeleton is necessary for podocyte migration [42], [43], [50]. 
Thus, the results of my experiments show that SIRT1 is required for the appropriate reorganization of 
actin cytoskeleton in podocytes. 
  SIRT1 belongs to the HDAC family, which acts to deacetylate proteins and histones, and controls 
epigenetic changes and protein functions [9], [51–54]. SIRT1 contributes to the regulation of patho-
genic intracellular signaling in podocytes. Chuang and colleagues demonstrated that SIRT1 overex-
pression in cultured murine podocytes prevents glycative stress-induced apoptosis under diabetic 
conditions [35], while Yuan and colleagues showed that SIRT1 prevents aldosterone-induced mito-
chondrial dysfunction and the subsequent apoptosis of podocytes [36]. Both studies highlight the link 
between the podocyte-protective effect of SIRT1 and podocyte apoptosis. I directly verified the func-
tion of SIRT1 in podocytes using novel genetically engineered podocyte-specific knockout mice, and 
elucidated the underlying mechanisms for this phenomenon in vivo using pharmacological methods 
in cultured podocytes in vitro. My results revealed a novel function of SIRT1 in podocytes: SIRT1, 
particularly its deacetylase activity against cortactin, protects podocyte homeostasis via the mainte-
nance of actin cytoskeleton. My experiments therefore directly reveal for the first time the functional 
role and biological mechanism of SIRT1 expressed in podocytes. 
Cortactin is an actin filament-binding substrate of Src tyrosine kinase [55], [56] which regulates 
the assembly, polymerization, and stabilization of the branched actin network [45], [57–59]. Recent 
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papers demonstrated that deacetylation is also important in the association of cortactin with F-actin 
and the promotion of actin assembly and stabilization of actin fibers in cancer cells [45], [46]. These 
findings are consistent with my present data observed in podocytes. Although the colocalization of 
cortactin with actin fibers in podocytes has been reported [60], [61], the function and regulation of 
cortactin has remained unclear. My present study revealed that the suppression of SIRT1 expression 
under pathogenic conditions, such as oxidative stress-related podocyte injury, induced the derange-
ment of actin cytoskeleton via the acetylation of cortactin, indicating a critical link between SIRT1 
and cortactin in podocyte homeostasis.  
Another novel finding of my study was that SIRT1 is required for the nuclear-cytoplasmic shuttle 
of cortactin in podocytes. I assessed changes in the amount of total or acetylated cortactin in the cy-
toplasm and nuclei of glomeruli of SIRT
pod-/-
 mice and of cultured podocytes with modulated SIRT1 
activity. Acetylated cortactin was mainly detected in the nuclei and its level was inversely correlated 
with SIRT1 activity. Considered together with the finding that SIRT1 is coprecipitated with cortactin, 
it is likely that SIRT1 is necessary for the transport of cortactin from nucleus to cytoplasm. The reg-
ulatory role of posttranslational acetylation on the nuclear import and export of proteins is well 
known [62]. In particular, nuclear protein LKB1 is exported to the cytoplasm following deacetylation 
by SIRT1 [63]. Based on these findings, my results strongly suggest that SIRT1 regulates cortactin 
localization by deacetylation. 
In this study, I investigated the alteration of kidney of SIRT1pod-/- mice after glomerular disease 
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induction by anti-GBM antibody. From other viewpoints, considering that Sirt1 is deeply associated 
with longevity, it is possible that these knockout mice without any stimulation show glomerular in-
jury or albuminuria in an advanced age such as 1 or 2 year-old. I should investigate whether some 
kind of injuries are induced in aged SIRT1
pod-/-
 mice. Moreover, the various role of Sirt1 includes 
regulation of inflammation. I examined the macrophage infiltration to glomeruli in glomerular dam-
age-induced SIRT1
pod-/-
 mice and found a tendency to increase in the number of the cells compared 
to wild-type mice (data not shown). In anti-GBM nephritis, glomerular inflammation was certainly 
caused and the exacerbation of inflammatory reaction might be one of the reasons which induced 
more severe podocyte injury in SIRT1
pod-/-
 mice. In any cases, the primary function of Sirt1 in podo-
cytes is a protection of the cells under the pathological condition rather than the maintenance of the 
cells in a physiological state. 
I have some limitations in this study. The first point is that podocyte-specific deletion of Sirt1 was 
not verified completely. However, I utilized Cre-recombinase / loxP system to make podo-
cyte-specific Sirt1 knockout mice, which is widely approved and reported in many previous 
studies[64–67]. In addition, I confirmed that the expression of SIRT1 was decreased by western blot 
analysis using isolated glomeruli of experimental mice. Therefore, it is reasonable to regard the po-
docin-Cre positive and Sirt1
flox/flox
 mice I made as podocyte-specific Sirt1 knockout mice. Secondly, 
the causal relationship between cytoplasmic cortactin and actin fiber derangement was assessed in-
sufficiently. To specify the interaction between cortactin and actin fiber, actin cytoskeleton derange-
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ment by cortactin knock down or inhibition of nuclear export of cortactin should be observed. In ad-
dition, immunoprecipitation for investigating the interaction between actin fiber and cortactin may be 
helpful to demonstrate this problem. Nonetheless, my hypothesis should be acceptable since cortactin 
is generally considered as an actin fiber-binding protein, even in podocytes, and my data also 
demonstrated that the dissociation of cortactin from actin fiber by SIRT1 inhibition surely induced 
actin cytoskeleton derangement. Finally, I could not confirm the total cortactin localization in vivo 
because the antibodies to cortactin we used did not work for IHC. Further investigation is necessary 
to confirm the localization and distribution of cortactin in the experimental mice.    
  In conclusion, I found that SIRT1 deacetylates cortactin in the nucleus, and that the deacetylated 
cortactin in cytoplasm predominantly interacts with actin fibers to enhance maintenance of actin cy-
toskeleton in podocytes. In contrast, inhibition of SIRT1 enhances the accumulation of acetylated 
cortactin in the nucleus and accelerates actin cytoskeleton derangement. The SIRT1-cortactin-actin 
fiber interaction regulates podocyte homeostasis and protects the cells against pathogenic conditions, 
suggesting that the optimization of SIRT1 activity may be important for podocyte biology.  
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